James Halley

A big buy by an asset manager spurred interest in the biotech stock.

The clinical-stage biotech just had its IPO last week.

The company's shares rose in response to a competitors' mixed phase 3 trial.

A mixed trial could hurt a kidney drug's chances of full approval.

Medtronic's history of innovation and dividend growth make for a good combination for investors.

The company received a Complete Response Letter from the FDA regarding its lead therapy.

All three companies should benefit from increased COVID-19 booster sales.

The company announced a chief financial officer transition plan.

The company got approval from the FDA to go ahead with a pivotal study for a hypertension therapy.

The company's shares are being dragged down by its soon-to-be-former parent company.

The company's stock rally began on Friday.

Insiders sold more than 15,000 shares of company stock on Tuesday.

The company's founder is spending his own money to help finance the business's efforts.

The high cost of developing drugs makes the use of artificial intelligence a natural fit for pharmaceutical companies.

Revenue at all three companies improved last quarter, and their share prices have followed suit.

The company got the go-ahead last week from the FDA for a drug's IND.

The biotech stock's lead therapy is looking at some competition.

The late-stage pharmaceutical company said it had reached an agreement with the Food and Drug Administration regarding a phase 2 trial for a Danon disease therapy.

The company had a big leadership change after an investigation.

The company announced a big reorganization.